Präsidentenposter: Early versus delayed treatment of acute hepatitis C: The German HEP-NET acute HCV-III study – a randomized controlled trial
K Deterding, N Grüner, J Wiegand, P Buggisch, P Galle, U Spengler, H Hinrichsen, T Berg, M Cornberg, A Potthoff, H Diepolder, S Feyerabend, MC Jung, MP Manns, H Wedemeyer · Zeitschrift für Gastroenterologie · 2009 · Heft 09
Bibliografische Angaben
Zusammenfassung
Early treatment of acute hepatitis C virus (HCV) infection with interferon alpha monotherapy is highly effective with SVR rates of >85%. However, an alternative strategy might be to delay treatment for 3 months and only to treat those patients who are not able to clear HCV spontaneously. The Hep-Net-Acute-HCV-III study was designed in 2004 as a prospective, randomized study in patients with symptomatic acute hepatitis C comparing the efficacy and safety of immediate PEG-IFNa-2b treatment for 6 months (arm-A) versus delayed treatment with PEG-IFNa-2b plus ribavirin for 6 months starting 12 weeks after randomisati…
